UK NEQAS
Blood Coagulation

Sheffield Teaching Hospitals NHS
NHS Foundation Trust

3rd Floor, Pegasus House,
463A Glossop Road,
Sheffield S10 2QD, UK
Tel: +44 (0)114 267 3300
Fax: +44 (0)114 267 3309
E-mail: neqas@coagega.org.uk
Website: www.ukneqasbc.org

Professor ID Walker (Director)
Dr S Kitchen (Scientific Director)
Dr I Jennings (Manager)
Mr C Reilly-Stitt (Scientific Programme Manager)
Mrs A Williams (Scientific lead Haemophilia Programmes)

Participant no

FVIII Inhibitor survey: Supplementary exercise

Distribution date July 2023

Closing date: Friday 8th September 2023

Instructions

Please read all the instructions and method details very carefully. Enclosed in this pack are 2 x 0.5ml Lyophilised plasma samples labelled FVIII IN 23:03 and FVIII IN 23:04. These samples should be refrigerated upon arrival. The samples are for quantitation of ***Human FVIII inhibitor titre***

The following clinical scenarios are given. Please carry out your investigation based on the information provided – stocks of samples in this exercise are limited, and repeat samples are not likely to be available.

Sample **FVIII IN 23:03** is from a patient with severe haemophilia A, who has an inhibitor and is having a routine clinic check up. Sample **FVIII IN 23:04** is from an unknown emergency admission patient, with a large haematoma at the hip. The patient was found to be carrying a medical card with details of being a patient with severe haemophilia A, further laboratory monitoring is required to check for FVIII inhibitors.

- For sample **FVIII IN 23:03 & FVIII IN 23:04**, please perform a **FVIII inhibitor assay** on this sample, using your routine method for this investigation, (for both samples the FVIII level <0.05IU/ml).

Sample **FVIII IN 23:03 & FVIII IN 23:04** should be stored refrigerated. Reconstitute by carefully adding **0.5 ml** of distilled water to each vial, mix gently and leave standing at room temperature for 10 minutes before testing.

Please return your results by email attachment to neqas@coagega.org.uk, closing date **Friday 8th September 2023**

Important note. *Samples have been screened for virology : hepatitis B surface antigen (HBsAg) and antibodies to human immunodeficiency virus types 1 & 2 (anti-HIV-1+2),were not detected. Hepatitis C RNA was also not detected. Samples have either been collected before the covid-19 pandemic or have been screened for covid-19. Nevertheless, appropriate precautions should be taken in the handling and disposal of these samples.*

Participant number:

Results table for sample FVIII IN 23:03

	Human FVIII inhibitor assay FVIII IN 23:03
Bethesda Result (B.U.)	……B.U/mL
Interpretation of result	
Did you heat-treat this Neqas sample prior to performing the Bethesda assay? If yes, please state time period and temperature	Yes/No (please circle) Time……Temperature……..
Sample + normal control plasma incubation – **please state time and temperature**	Time……Temperature……..
Is the normal control material incubated with buffer or FVIII deficient plasma	Buffer / FVIII deficient plasma (please circle)
What is the source of buffer **(if used)**	
What is the source of normal control plasma	
What is the source of FVIII deficient plasma **(if used)**	
What method did you use to measure the residual FVIII level (one stage/chromogenic)	one stage / chromogenic (please circle)
What analyser did you use for this assay?	
What reagent was used to measure the residual FVIII on the analyser **(if applicable)**	
Please circle the dilutions & write the associated residual FVIII:C result in the table that were used for the Bethesda assay. If dilutions were used that are not present, please state in the blank boxes.	**1:1=** **1:2=** **1:3 =** **1:4 =** **1:5 =** **1:6 =** **1:8 =** **1:9 =** **1:10 =** **1:15 =** **1:20 =** **1:32 =** **1:40 =** **1:64 =** **1:80 =** **1:120 =** **1:164 =**

Participant number:

Result table for sample FVIII IN 23:04

	Human FVIII inhibitor assay FVIII IN 23:04
Bethesda Result (B.U.)	……B.U/mL
Interpretation of result	
Did you heat-treat this Neqas sample prior to performing the Bethesda assay? If yes, please state time period and temperature	Yes/No (please circle) Time……Temperature……..
Sample + normal control plasma incubation – **please state time and temperature**	Time……Temperature……..
Is the normal control material incubated with buffer or FVIII deficient plasma	Buffer / FVIII deficient plasma (please circle)
What is the source of buffer **(if used)**	
What is the source of normal control plasma	
What is the source of FVIII deficient plasma **(if used)**	
What method did you use to measure the residual FVIII level (one stage/chromogenic)	one stage / chromogenic (please circle)
What analyser did you use for this assay?	
What reagent was used to measure the residual FVIII on the analyser **(if applicable)**	
Please circle the dilutions & write the associated residual FVIII:C result in the table that were used for the Bethesda assay. If dilutions were used that are not present, please state in the blank boxes.	**1:1=** **1:2=** **1:3 =** **1:4 =** **1:5 =** **1:6 =** **1:8 =** **1:9 =** **1:10 =** **1:15 =** **1:20 =** **1:32 =** **1:40 =** **1:64 =** **1:80 =** **1:120 =** **1:164 =**